Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

Not Applicable

Completed

• Conditions: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Major Depression

• Registration Number: NCT00178932
• Lead Sponsor: Northwestern University

Brief Summary

The goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.

Detailed Description

Not available

Study Timeline

• Study Start: 1998-11
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-12
• Study First Posted: 2005-09-15
• Primary Completion: 2024-05-16
• Study Completion: 2024-05-16
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-13
• Last Update Posted: 2025-03-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

Patients with the diagnoses of schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features, or volunteers with no history of a psychotic disorder.

Exclusion Criteria

Patients with DSM-IV diagnoses other than schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
We plan to compare the polymorphisms across schizophrenic patients and adults who do not have a diagnosed major mental illness. .	single visit

Secondary Outcome Measures

Name	Time	Method
We will also evaluate relationships between the polymorphism and past and current mental health among the non-diagnosed sample	single visit

Trial Locations

Locations (1)

Psychiatric Hospital at Vanderbilt; 🇺🇸 Nashville, Tennessee, United States